ADIAL PHARMACEUTICALS, INC.
No enriched coverage for $ADIL in the last 7 days.
No SEC Form 4 filings for $ADIL in the last 30 days.
See all $ADIL insider activity →ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. Th
Adial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative
Recent ADIL coverage spans corporate actions, financial news and insider activity.
Potential dilution of shares if exercised; modest impact on float.
Financing plus the Azora (AT177) acquisition is a near-term balance-sheet and pipeline inflection, but dilution and large quarterly loss raise risk.
This is a routine quarterly financial disclosure via 8-K, but the scraped text does not include the actual financial results or guidance details.
Board and C-suite changes are likely to drive near-term sentiment and volatility, especially given the conditional nature tied to shareholder votes.
The stake increase may support downside stabilization, but it is not a company-issued catalyst.
alphai scores every news story that mentions ADIL with an AI model for sentiment and relevance, and aggregates insider trades from ADIAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. Th
1 min readAdial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.
4 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative
2 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President
3 min readInvesting.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
4 min readCoastlands Capital LP purchased 11,753 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at an average of $2.78 ($2.70–$2.79) across 2 trades over 2026-07-09 to 2026-07-10.
2 min readCoastlands Capital LP purchased 25,000 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.60 on 2026-06-29.
2 min readAdial Pharmaceuticals said it will acquire Azora Therapeutics and obtain its lead asset AT177 for ulcerative colitis. The deal is paired with a $64 million private placement, including $32 million upfront, issuing pre-funded warrants for 11,780,948 shares at $2.7489. A further $32 million milestone is tied to Phase 1 start. Proceeds will fund AT177 development; proof-of-concept studies are planned for 2027.
4 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029444801ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JUNE 11, BY AND AMONG ADIAL PHARMACEUTICALS, INC., ADIAL FIRST MERGER SUB, INC., ADIAL SECOND MERGER SUB, LLC AND AZORA THERAPEUTICS, INC Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among: Adi
6 min readAdial Pharmaceuticals is undergoing significant changes, focusing on an upcoming investor presentation and new data in the alcohol use disorder treatment market. The company recently completed a reverse stock split to maintain Nasdaq compliance and filed an international patent application to protect its intellectual property. CEO Cary Claiborne will present clinical advancements and strategic plans at Oppenheimer’s Healthcare Life Sciences Conference, offering investors clarity on the AD04 Phase 3 trial and potential partnerships.
4 min read